Profil
Dr. Lee B.
Bussey is Senior Vice President-Manufacturing at Juvaris Bio Therapeutics, Inc.
Dr. Bussey was previously employed as Vice President-Bioprocessing by Valentis, Inc., a Faculty Member by Georgia State University, and a Faculty Member by University of Illinois.
He received his undergraduate degree from the University of California, Davis and a doctorate degree from the University of California, Davis.
Anciens postes connus de Lee B. Bussey
| Sociétés | Poste | Fin |
|---|---|---|
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Corporate Officer/Principal | 01/01/2006 |
| Georgia State University | Corporate Officer/Principal | - |
| University of Illinois | Corporate Officer/Principal | - |
Juvaris BioTherapeutics, Inc.
 Juvaris BioTherapeutics, Inc. BiotechnologyHealth Technology Juvaris BioTherapeutics, Inc. develops novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The company was founded by Martin D. Cleary, Jeff Fairman and Steven W. Dow in February 2003 and is headquartered in Burlingame, CA. | Corporate Officer/Principal | - |
Formation de Lee B. Bussey
| University of California, Davis | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Juvaris BioTherapeutics, Inc.
Juvaris BioTherapeutics, Inc. BiotechnologyHealth Technology Juvaris BioTherapeutics, Inc. develops novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The company was founded by Martin D. Cleary, Jeff Fairman and Steven W. Dow in February 2003 and is headquartered in Burlingame, CA. | Health Technology |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
